NYSE:COO - The Cooper Companies Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $387.17
Forecasted Upside: 1.48 %
Number of Analysts: 11
Breakdown:
0 Sell Ratings
4 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$381.53 As of 06/16/2021 01:00 AM ET

▲ +4.66 (1.24%)

1 month | 3 months | 12 months

Get New The Cooper Companies Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for COO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$387.17

▲ +1.48% Upside Potential

This price target is based on 11 analysts offering 12 month price targets for The Cooper Companies in the last 3 months. The average price target is $387.17, with a high forecast of $450.00 and a low forecast of $315.00. The average price target represents a 1.48% upside from the last price of $381.53.

Buy

The current consensus among 11 polled investment analysts is to buy stock in The Cooper Companies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
9 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

12/24/2019

0 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/23/2020

0 strong buy ratings
8 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/21/2020

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

9/19/2020

0 strong buy ratings
7 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

12/18/2020

0 strong buy ratings
6 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/18/2021

0 strong buy ratings
7 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

5/17/2021

0 strong buy ratings
7 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/16/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
6/1/2021	Piper Sandler	Boost Price Target	Overweight	$435.00 ➝ $440.00	Medium	i
5/24/2021	Jefferies Financial Group	Reiterated Rating	Buy	$450.00	Low	i Rating by Raj Denhoy at Jefferies Financial Group Inc.
4/28/2021	KeyCorp	Boost Price Target	Overweight	$429.00 ➝ $444.00	Low	i
4/23/2021	Redburn Partners	Initiated Coverage	Buy		Medium	i
3/8/2021	KeyCorp	Boost Price Target	Overweight	$425.00 ➝ $429.00	Medium	i
3/5/2021	Citigroup	Boost Price Target	Neutral	$355.00 ➝ $378.00	High	i
3/5/2021	Jefferies Financial Group	Boost Price Target	Buy	$425.00 ➝ $435.00	High	i
3/5/2021	Raymond James	Boost Price Target	Outperform	$375.00 ➝ $415.00	High	i
3/5/2021	Robert W. Baird	Boost Price Target	Neutral	$351.00 ➝ $384.00	High	i
3/1/2021	KeyCorp	Boost Price Target	Overweight	$425.00 ➝ $429.00	Low	i
2/23/2021	KeyCorp	Boost Price Target	Overweight	$396.00 ➝ $425.00	Low	i
2/11/2021	Piper Sandler	Boost Price Target	Overweight	$370.00 ➝ $435.00	Low	i
1/25/2021	Wells Fargo & Company	Boost Price Target		$415.00 ➝ $445.00	Medium	i
1/8/2021	KeyCorp	Boost Price Target	Overweight	$367.00 ➝ $396.00	Medium	i
12/4/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target		$330.00 ➝ $335.00	Medium	i
12/4/2020	Smith Barney Citigroup	Boost Price Target		$330.00 ➝ $335.00	Medium	i
12/4/2020	Piper Sandler	Boost Price Target	Overweight	$351.00 ➝ $370.00	High	i
12/4/2020	KeyCorp	Boost Price Target	Overweight	$349.00 ➝ $367.00	High	i
11/20/2020	Wells Fargo & Company	Boost Price Target	Overweight	$360.00 ➝ $380.00	Low	i
9/24/2020	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
9/17/2020	Raymond James	Boost Price Target	Positive ➝ Outperform	$330.00 ➝ $375.00	Medium	i
9/4/2020	JPMorgan Chase & Co.	Boost Price Target	Neutral	$285.00 ➝ $315.00	High	i
9/4/2020	Oppenheimer	Boost Price Target	Market Perform	$330.00 ➝ $340.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
9/4/2020	Raymond James	Reiterated Rating	Buy		High	i
9/4/2020	Stephens	Boost Price Target	Overweight	$325.00 ➝ $365.00	High	i
9/4/2020	Citigroup	Boost Price Target	Neutral	$310.00 ➝ $330.00	High	i
9/4/2020	KeyCorp	Boost Price Target	Positive ➝ Overweight	$330.00 ➝ $349.00	High	i
7/6/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$335.00 ➝ $291.00	High	i Rating by Jeff Johnson at Robert W. Baird
6/5/2020	Oppenheimer	Initiated Coverage	Hold	$330.00	Low	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/5/2020	Raymond James	Lower Price Target	Outperform	$340.00 ➝ $330.00	High	i
5/26/2020	Stephens	Boost Price Target	Overweight	$300.00 ➝ $325.00	High	i
5/26/2020	KeyCorp	Lower Price Target	Overweight	$380.00 ➝ $330.00	High	i
5/21/2020	Wells Fargo & Company	Lower Price Target	Overweight	$388.00 ➝ $329.00	High	i
4/21/2020	Raymond James	Lower Price Target	Outperform	$360.00 ➝ $340.00	High	i
4/8/2020	Jefferies Financial Group	Lower Price Target	Buy	$360.00 ➝ $340.00	High	i
3/27/2020	Citigroup	Lower Price Target	Neutral	$360.00 ➝ $318.00	Medium	i
3/23/2020	Stephens	Lower Price Target	Overweight	$375.00 ➝ $300.00	Low	i
3/6/2020	Piper Sandler	Boost Price Target		$344.00 ➝ $351.00	High	i
3/6/2020	Stifel Nicolaus	Boost Price Target	Buy	$320.00 ➝ $350.00	High	i
3/6/2020	Robert W. Baird	Boost Price Target	Outperform	$345.00 ➝ $357.00	High	i Rating by Jeff Johnson at Robert W. Baird
3/6/2020	Stephens	Boost Price Target	Overweight	$340.00 ➝ $375.00	High	i
3/6/2020	Raymond James	Boost Price Target	Outperform	$355.00 ➝ $360.00	High	i
3/4/2020	Citigroup	Initiated Coverage	Neutral	$360.00	High	i
1/22/2020	KeyCorp	Boost Price Target	Overweight	$351.00 ➝ $380.00	Low	i Rating by Matthew Mishan at KeyCorp
1/16/2020	Wells Fargo & Company	Boost Price Target	Overweight	$360.00 ➝ $388.00	Medium	i
12/6/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$344.00	Low	i Rating by Matthew O'Brien at Piper Jaffray Companies
12/6/2019	Robert W. Baird	Reiterated Rating	Buy	$345.00	Low	i Rating by Jeff Johnson at Robert W. Baird
12/6/2019	Raymond James	Lower Price Target	Buy ➝ In-Line	$364.00 ➝ $355.00	High	i Rating by Lawrence Keusch at Raymond James
12/4/2019	Jefferies Financial Group	Lower Price Target	Average ➝ In-Line	$358.00 ➝ $330.00	Low	i
12/3/2019	Northcoast Research	Reiterated Rating	Buy		Low	i Rating by D. Keiser at Northcoast Research
11/27/2019	KeyCorp	Boost Price Target	Overweight	$348.00 ➝ $351.00	Low	i Rating by Matthew Mishan at KeyCorp
10/11/2019	KeyCorp	Lower Price Target	Overweight	$351.00 ➝ $348.00	Low	i Rating by Matthew Mishan at KeyCorp
8/30/2019	Piper Jaffray Companies	Set Price Target	Buy	$360.00	Medium	i Rating by Matthew O'Brien at Piper Jaffray Companies
8/30/2019	KeyCorp	Set Price Target	Buy	$351.00	Medium	i Rating by Matthew Mishan at KeyCorp
8/26/2019	Raymond James	Reiterated Rating	Buy		Low	i Rating by Lawrence Keusch at Raymond James
8/22/2019	KeyCorp	Boost Price Target	Overweight ➝ Overweight	$314.00 ➝ $351.00	Low	i
8/13/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$330.00 ➝ $360.00	Medium	i
8/8/2019	Wells Fargo & Company	Boost Price Target	Outperform	$356.00 ➝ $365.00	Low	i
7/2/2019	Raymond James	Boost Price Target	Outperform	$325.00 ➝ $364.00	High	i
6/10/2019	Wells Fargo & Company	Boost Price Target	Outperform	$325.00 ➝ $356.00	Low	i
6/3/2019	Northcoast Research	Reiterated Rating	Positive ➝ Buy	$331.00 ➝ $340.00	Low	i
3/6/2019	Jefferies Financial Group	Boost Price Target	Buy	$330.00	Low	i
3/6/2019	Wells Fargo & Company	Boost Price Target	Outperform	$305.00 ➝ $325.00	Medium	i
3/6/2019	Stephens	Boost Price Target	Overweight	$305.00 ➝ $320.00	High	i
3/6/2019	Raymond James	Boost Price Target	Outperform ➝ Outperform	$300.00 ➝ $325.00	High	i
3/6/2019	KeyCorp	Boost Price Target	Overweight	$296.00 ➝ $314.00	High	i
3/6/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$306.00 ➝ $320.00	High	i
3/6/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$325.00	High	i
2/1/2019	Stephens	Upgrade	Equal Weight ➝ Overweight	$305.00	Low	i
1/12/2019	William Blair	Reiterated Rating	Outperform		High	i Rating by B. Weinstein at William Blair
1/4/2019	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$233.00 ➝ $221.00	Medium	i
12/9/2018	KeyCorp	Reiterated Rating	Buy		High	i
12/7/2018	Oppenheimer	Set Price Target	Hold	$282.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
12/7/2018	Wells Fargo & Company	Boost Price Target	Outperform ➝ Outperform	$295.00 ➝ $305.00	High	i
12/7/2018	Jefferies Financial Group	Boost Price Target	Buy	$305.00	High	i
12/7/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$294.00 ➝ $306.00	High	i
12/7/2018	KeyCorp	Lower Price Target	Overweight ➝ Overweight	$298.00 ➝ $296.00	High	i
11/12/2018	Wells Fargo & Company	Boost Price Target	Outperform ➝ Outperform	$290.00 ➝ $295.00	High	i
9/21/2018	Raymond James	Boost Price Target	Outperform ➝ Outperform	$270.00 ➝ $300.00	Low	i
8/31/2018	Oppenheimer	Set Price Target	Hold	$270.00	Medium	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/31/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$280.00 ➝ $285.00	High	i
6/8/2018	Oppenheimer	Set Price Target	Hold	$265.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/5/2018	Raymond James	Lower Price Target	Outperform ➝ Outperform	$275.00 ➝ $270.00	Low	i
4/4/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$231.00	Low	i Rating by Issac Ro at The Goldman Sachs Group, Inc.
3/29/2018	Oppenheimer	Set Price Target	Hold	$265.00	N/A	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
3/9/2018	BMO Capital Markets	Reiterated Rating	Outperform ➝ Outperform	$277.00 ➝ $280.00	Low	i
3/9/2018	Oppenheimer	Set Price Target	Hold	$265.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
3/9/2018	Stephens	Reiterated Rating	Hold	$270.00	Medium	i
3/9/2018	Jefferies Financial Group	Reiterated Rating	Buy	$285.00	Medium	i
2/9/2018	Cleveland Research	Downgrade	Buy ➝ Hold		Low	i Rating by Steve Willoughby at Cleveland Research
12/8/2017	Oppenheimer	Set Price Target	Hold	$250.00	Medium	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
12/8/2017	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$275.00 ➝ $265.00	High	i
12/4/2017	Raymond James	Reiterated Rating	Buy	$265.00	Medium	i
10/20/2017	KeyCorp	Reiterated Rating	Hold		N/A	i
10/16/2017	Robert W. Baird	Set Price Target	Buy	$273.00	N/A	i Rating by Jeff Johnson at Robert W. Baird
10/13/2017	BMO Capital Markets	Reiterated Rating	Buy	$272.00	N/A	i
9/12/2017	Jefferies Financial Group	Reiterated Rating	Buy	$250.00	Low	i Rating by Steven Desanctis at Jefferies Financial Group Inc.
9/12/2017	Stephens	Reiterated Rating	Equal Weight	$235.00 ➝ $250.00	Low	i
9/12/2017	Oppenheimer	Reiterated Rating	Hold	$250.00	Medium	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
9/12/2017	Robert W. Baird	Reiterated Rating	Buy	$267.00 ➝ $273.00	Medium	i
9/12/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold	$235.00	Medium	i
9/12/2017	Stifel Nicolaus	Boost Price Target	Buy	$265.00 ➝ $275.00	High	i
9/3/2017	Robert W. Baird	Reiterated Rating	Buy	$251.00 ➝ $267.00	Medium	i
9/1/2017	BMO Capital Markets	Reiterated Rating	Buy	$272.00	N/A	i
9/1/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$265.00 ➝ $280.00	High	i
8/28/2017	KeyCorp	Reiterated Rating	Hold		Low	i
8/24/2017	Robert W. Baird	Reiterated Rating	Buy	$251.00	Low	i
8/22/2017	Cleveland Research	Reiterated Rating	Buy		Low	i Rating by Steve Willoughby at Cleveland Research
8/17/2017	Jefferies Financial Group	Set Price Target	Buy	$250.00	Low	i Rating by Steven Desanctis at Jefferies Financial Group Inc.
7/21/2017	KeyCorp	Reiterated Rating	Overweight ➝ Sector Weight		Medium	i
7/19/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$265.00	Low	i
7/13/2017	BMO Capital Markets	Reiterated Rating	Buy	$255.00	Medium	i
7/6/2017	Jefferies Financial Group	Reiterated Rating	Buy	$250.00	High	i
7/6/2017	Robert W. Baird	Boost Price Target	Outperform	$239.00 ➝ $251.00	Low	i
6/29/2017	Guggenheim	Initiated Coverage	Neutral		High	i
6/5/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral	$200.00 ➝ $206.00	Low	i
6/5/2017	BMO Capital Markets	Reiterated Rating	Outperform	$220.00 ➝ $255.00	Low	i Rating by Joanne Wuensch at BMO Capital Markets
6/3/2017	Oppenheimer	Set Price Target	Hold	$225.00	Medium	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/3/2017	Jefferies Financial Group	Reiterated Rating	Buy	$220.00 ➝ $250.00	Medium	i
6/2/2017	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$220.00 ➝ $231.00	High	i
4/6/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$220.00	Low	i
3/4/2017	Oppenheimer	Set Price Target	Hold	$203.00	N/A	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
3/3/2017	Jefferies Financial Group	Boost Price Target	Buy	$210.00 ➝ $220.00	N/A	i
3/3/2017	BMO Capital Markets	Reiterated Rating	Buy		N/A	i Rating by Joanne Wuensch at BMO Capital Markets
12/12/2016	Wells Fargo & Company	Upgrade	Market Perform ➝ Outperform		N/A	i
12/9/2016	Oppenheimer	Set Price Target	Hold	$188.00	N/A	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
12/9/2016	BMO Capital Markets	Set Price Target	Buy	$206.00 ➝ $203.00	N/A	i Rating by Joanne Wuensch at BMO Capital Markets
12/7/2016	Jefferies Financial Group	Reiterated Rating	Buy	$210.00	N/A	i
10/1/2016	KeyCorp	Set Price Target	Buy	$221.00	N/A	i Rating by Matthew Mishan at KeyCorp
9/11/2016	Wells Fargo & Company	Reiterated Rating	Hold		N/A	i Rating by Larry Biegelsen at Wells Fargo & Company
9/9/2016	Stifel Nicolaus	Reiterated Rating	Buy	$215.00	N/A	i Rating by Jonathan Block at Stifel Nicolaus
9/2/2016	BMO Capital Markets	Boost Price Target	Outperform	$199.00 ➝ $206.00	N/A	i
9/2/2016	Stifel Nicolaus	Reiterated Rating	Buy ➝ In-Line		N/A	i Rating by Jonathan Block at Stifel Nicolaus
8/31/2016	Stifel Nicolaus	Boost Price Target	Buy	$195.00 ➝ $215.00	N/A	i Rating by Jonathan Block at Stifel Nicolaus
8/24/2016	Jefferies Financial Group	Boost Price Target	Buy	$190.00 ➝ $210.00	N/A	i Rating by Anthony Petrone at Jefferies Financial Group Inc.
8/18/2016	Robert W. Baird	Boost Price Target	Outperform	$185.00 ➝ $196.00	N/A	i Rating by Jeff Johnson at Robert W. Baird
7/26/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$185.00	N/A	i Rating by Matthew O'Brien at Piper Jaffray Companies
7/13/2016	JPMorgan Chase & Co.	Initiated Coverage	Buy		N/A	i
6/30/2016	Stifel Nicolaus	Boost Price Target	Buy	$180.00 ➝ $195.00	N/A	i
6/25/2016	Robert W. Baird	Reiterated Rating	Outperform	$185.00	N/A	i Rating by Jeff Johnson at Robert W. Baird

(Data available from 6/16/2016 forward)

The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.

Today's Range

Now: $381.53

$377.00

$383.99

50 Day Range

MA: $392.59

$372.36

$412.07

52 Week Range

Now: $381.53

$268.92

$415.96

Volume

367,067 shs

Average Volume

279,965 shs

Market Capitalization

$18.79 billion

P/E Ratio

8.04

Dividend Yield

0.02%

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of The Cooper Companies?

The following Wall Street analysts have issued research reports on The Cooper Companies in the last twelve months: Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Jefferies Financial Group Inc., JPMorgan Chase & Co., KeyCorp, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Redburn Partners, Robert W. Baird, Smith Barney Citigroup, Stephens, TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for COO.

What is the current price target for The Cooper Companies?

12 Wall Street analysts have set twelve-month price targets for The Cooper Companies in the last year. Their average twelve-month price target is $387.17, suggesting a possible upside of 1.5%. Jefferies Financial Group Inc. has the highest price target set, predicting COO will reach $450.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $315.00 for The Cooper Companies in the next year.
View the latest price targets for COO.

What is the current consensus analyst rating for The Cooper Companies?

The Cooper Companies currently has 4 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe COO will outperform the market and that investors should add to their positions of The Cooper Companies.
View the latest ratings for COO.

What other companies compete with The Cooper Companies?

Other companies that are similar to The Cooper Companies include Align Technology, West Pharmaceutical Services, DENTSPLY SIRONA, STAAR Surgical, Neogen, Quidel, ICU Medical, Merit Medical Systems, Haemonetics, Atrion, Cerus, Meridian Bioscience, Antares Pharma, OraSure Technologies and Anika Therapeutics.

How do I contact The Cooper Companies' investor relations team?

The Cooper Companies' physical mailing address is 6101 Bollinger Canyon Road Suite 500, San Ramon CA, 94583. The medical device company's listed phone number is 925-460-3600 and its investor relations email address is [email protected] The official website for The Cooper Companies is www.coopercos.com.